MovDisordV3, PascalFrancis, Corpus, bibRecord, 000F69

BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline

Identifieur interne : 000F69 ( PascalFrancis/Corpus ); précédent : 000F68; suivant : 000F70

BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline

Auteurs : Roger Lane ; YUNSHENG HE ; Christopher Morris ; James B. Leverenz ; Murat Emre ; Clive Ballard

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0136787

Descripteurs français

Pascal (Inist)
- Démence à corps de Lewy, Hyperhomocystéinémie, Trouble cognitif, Maladie de Parkinson, Pathologie du système nerveux, Génotype, Apolipoprotéine E.

English descriptors

KwdEn :
- Apolipoprotein E, Cognitive disorder, Genotype, Hyperhomocysteinemia, Lewy body dementia, Nervous system diseases, Parkinson disease.

Abstract

Apolipoprotein E (APOE) e4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample, associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE e4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other genotypes. Subjects with hyperhomocysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE ε4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline`
A11	`01`	`1`		`@1 LANE (Roger)`
A11	`02`	`1`		`@1 YUNSHENG HE`
A11	`03`	`1`		`@1 MORRIS (Christopher)`
A11	`04`	`1`		`@1 LEVERENZ (James B.)`
A11	`05`	`1`		`@1 EMRE (Murat)`
A11	`06`	`1`		`@1 BALLARD (Clive)`
A14	`01`			`@1 Novartis Pharmaceuticals Corporation @2 East Hanover, New Jersey @3 USA @Z 1 aut.`
A14	`02`			`@1 Clinical Pharmacogenetics, Novartis Pharmaceuticals Corporation @2 Cambridge, Massachusetts @3 USA @Z 2 aut.`
A14	`03`			`@1 Newcastle General Hospital @2 Newcastle upon Tyne @3 GBR @Z 3 aut.`
A14	`04`			`@1 VA-Puget Sound Health Care System (MIRECC, PADRECC) and University of Washington @2 Seattle, Washington @3 USA @Z 4 aut.`
A14	`05`			`@1 Istanbul Faculty of Medicine, Istanbul University @2 Istanbul @3 TUR @Z 5 aut.`
A14	`06`			`@1 Wolfson Centre for Age Related Diseases, King's College @2 London @3 GBR @Z 6 aut.`
A20				`@1 392-400`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000186999840110`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 22 ref.`
A47	`01`	`1`		`@0 09-0136787`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Apolipoprotein E (APOE) e4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample, associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE e4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other genotypes. Subjects with hyperhomocysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE ε4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Démence à corps de Lewy @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Lewy body dementia @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Demencia cuerpos Lewy @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Hyperhomocystéinémie @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Hyperhomocysteinemia @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Hiperhomocisteinemia @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Trouble cognitif @5 03`
C03	`03`	`X`	`ENG`	`@0 Cognitive disorder @5 03`
C03	`03`	`X`	`SPA`	`@0 Trastorno cognitivo @5 03`
C03	`04`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 04`
C03	`04`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 04`
C03	`04`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 04`
C03	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 05`
C03	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 05`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 05`
C03	`06`	`X`	`FRE`	`@0 Génotype @5 10`
C03	`06`	`X`	`ENG`	`@0 Genotype @5 10`
C03	`06`	`X`	`SPA`	`@0 Genotipo @5 10`
C03	`07`	`X`	`FRE`	`@0 Apolipoprotéine E @5 11`
C03	`07`	`X`	`ENG`	`@0 Apolipoprotein E @5 11`
C03	`07`	`X`	`SPA`	`@0 Apolipoproteína E @5 11`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 096`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0136787 INIST
ET :	BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline
AU :	LANE (Roger); YUNSHENG HE; MORRIS (Christopher); LEVERENZ (James B.); EMRE (Murat); BALLARD (Clive)
AF :	Novartis Pharmaceuticals Corporation/East Hanover, New Jersey/Etats-Unis (1 aut.); Clinical Pharmacogenetics, Novartis Pharmaceuticals Corporation/Cambridge, Massachusetts/Etats-Unis (2 aut.); Newcastle General Hospital/Newcastle upon Tyne/Royaume-Uni (3 aut.); VA-Puget Sound Health Care System (MIRECC, PADRECC) and University of Washington/Seattle, Washington/Etats-Unis (4 aut.); Istanbul Faculty of Medicine, Istanbul University/Istanbul/Turquie (5 aut.); Wolfson Centre for Age Related Diseases, King's College/London/Royaume-Uni (6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 3; Pp. 392-400; Bibl. 22 ref.
LA :	Anglais
EA :	Apolipoprotein E (APOE) e4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample, associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE e4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other genotypes. Subjects with hyperhomocysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE ε4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders.
CC :	002B17; 002B17G
FD :	Démence à corps de Lewy; Hyperhomocystéinémie; Trouble cognitif; Maladie de Parkinson; Pathologie du système nerveux; Génotype; Apolipoprotéine E
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Lewy body dementia; Hyperhomocysteinemia; Cognitive disorder; Parkinson disease; Nervous system diseases; Genotype; Apolipoprotein E
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Demencia cuerpos Lewy; Hiperhomocisteinemia; Trastorno cognitivo; Parkinson enfermedad; Sistema nervioso patología; Genotipo; Apolipoproteína E
LO :	INIST-20953.354000186999840110
ID :	09-0136787

Links to Exploration step

Pascal:09-0136787

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline</title>
<author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name>
<affiliation><inist:fA14 i1="01"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, New Jersey</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yunsheng He" sort="Yunsheng He" uniqKey="Yunsheng He" last="Yunsheng He">YUNSHENG HE</name>
<affiliation><inist:fA14 i1="02"><s1>Clinical Pharmacogenetics, Novartis Pharmaceuticals Corporation</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morris, Christopher" sort="Morris, Christopher" uniqKey="Morris C" first="Christopher" last="Morris">Christopher Morris</name>
<affiliation><inist:fA14 i1="03"><s1>Newcastle General Hospital</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leverenz, James B" sort="Leverenz, James B" uniqKey="Leverenz J" first="James B." last="Leverenz">James B. Leverenz</name>
<affiliation><inist:fA14 i1="04"><s1>VA-Puget Sound Health Care System (MIRECC, PADRECC) and University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name>
<affiliation><inist:fA14 i1="05"><s1>Istanbul Faculty of Medicine, Istanbul University</s1>
<s2>Istanbul</s2>
<s3>TUR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ballard, Clive" sort="Ballard, Clive" uniqKey="Ballard C" first="Clive" last="Ballard">Clive Ballard</name>
<affiliation><inist:fA14 i1="06"><s1>Wolfson Centre for Age Related Diseases, King's College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0136787</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0136787 INIST</idno>
<idno type="RBID">Pascal:09-0136787</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F69</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline</title>
<author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name>
<affiliation><inist:fA14 i1="01"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, New Jersey</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yunsheng He" sort="Yunsheng He" uniqKey="Yunsheng He" last="Yunsheng He">YUNSHENG HE</name>
<affiliation><inist:fA14 i1="02"><s1>Clinical Pharmacogenetics, Novartis Pharmaceuticals Corporation</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morris, Christopher" sort="Morris, Christopher" uniqKey="Morris C" first="Christopher" last="Morris">Christopher Morris</name>
<affiliation><inist:fA14 i1="03"><s1>Newcastle General Hospital</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leverenz, James B" sort="Leverenz, James B" uniqKey="Leverenz J" first="James B." last="Leverenz">James B. Leverenz</name>
<affiliation><inist:fA14 i1="04"><s1>VA-Puget Sound Health Care System (MIRECC, PADRECC) and University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name>
<affiliation><inist:fA14 i1="05"><s1>Istanbul Faculty of Medicine, Istanbul University</s1>
<s2>Istanbul</s2>
<s3>TUR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ballard, Clive" sort="Ballard, Clive" uniqKey="Ballard C" first="Clive" last="Ballard">Clive Ballard</name>
<affiliation><inist:fA14 i1="06"><s1>Wolfson Centre for Age Related Diseases, King's College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apolipoprotein E</term>
<term>Cognitive disorder</term>
<term>Genotype</term>
<term>Hyperhomocysteinemia</term>
<term>Lewy body dementia</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Démence à corps de Lewy</term>
<term>Hyperhomocystéinémie</term>
<term>Trouble cognitif</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Génotype</term>
<term>Apolipoprotéine E</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Apolipoprotein E (APOE) e4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample, associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE e4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other genotypes. Subjects with hyperhomocysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE ε4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LANE (Roger)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>YUNSHENG HE</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MORRIS (Christopher)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LEVERENZ (James B.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>EMRE (Murat)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BALLARD (Clive)</s1>
</fA11>
<fA14 i1="01"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, New Jersey</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Clinical Pharmacogenetics, Novartis Pharmaceuticals Corporation</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Newcastle General Hospital</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>VA-Puget Sound Health Care System (MIRECC, PADRECC) and University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Istanbul Faculty of Medicine, Istanbul University</s1>
<s2>Istanbul</s2>
<s3>TUR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Wolfson Centre for Age Related Diseases, King's College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>392-400</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000186999840110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>22 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0136787</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Apolipoprotein E (APOE) e4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample, associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE e4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other genotypes. Subjects with hyperhomocysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE ε4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Démence à corps de Lewy</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lewy body dementia</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Demencia cuerpos Lewy</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Hyperhomocystéinémie</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Hyperhomocysteinemia</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hiperhomocisteinemia</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Trouble cognitif</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Cognitive disorder</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Trastorno cognitivo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Génotype</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Genotype</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Genotipo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Apolipoprotéine E</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Apolipoprotein E</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Apolipoproteína E</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>096</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0136787 INIST</NO>
<ET>BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline</ET>
<AU>LANE (Roger); YUNSHENG HE; MORRIS (Christopher); LEVERENZ (James B.); EMRE (Murat); BALLARD (Clive)</AU>
<AF>Novartis Pharmaceuticals Corporation/East Hanover, New Jersey/Etats-Unis (1 aut.); Clinical Pharmacogenetics, Novartis Pharmaceuticals Corporation/Cambridge, Massachusetts/Etats-Unis (2 aut.); Newcastle General Hospital/Newcastle upon Tyne/Royaume-Uni (3 aut.); VA-Puget Sound Health Care System (MIRECC, PADRECC) and University of Washington/Seattle, Washington/Etats-Unis (4 aut.); Istanbul Faculty of Medicine, Istanbul University/Istanbul/Turquie (5 aut.); Wolfson Centre for Age Related Diseases, King's College/London/Royaume-Uni (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 3; Pp. 392-400; Bibl. 22 ref.</SO>
<LA>Anglais</LA>
<EA>Apolipoprotein E (APOE) e4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample, associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE e4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other genotypes. Subjects with hyperhomocysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE ε4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders.</EA>
<CC>002B17; 002B17G</CC>
<FD>Démence à corps de Lewy; Hyperhomocystéinémie; Trouble cognitif; Maladie de Parkinson; Pathologie du   système nerveux; Génotype; Apolipoprotéine E</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Lewy body dementia; Hyperhomocysteinemia; Cognitive disorder; Parkinson disease; Nervous system diseases; Genotype; Apolipoprotein E</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Demencia cuerpos Lewy; Hiperhomocisteinemia; Trastorno cognitivo; Parkinson enfermedad; Sistema nervioso patología; Genotipo; Apolipoproteína E</SD>
<LO>INIST-20953.354000186999840110</LO>
<ID>09-0136787</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F69 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000F69 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0136787
   |texte=   BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline

BuChE-K and APOE ε4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri